Some blood pressure medications are not the best choice anymore, either due to their side effects or limited effectiveness.

MINNEAPOLIS — The University of Minnesota College of Pharmacy released research Wednesday that lays the groundwork for the ...

Polyrizon (PLRZ) announced the structuring of its clinical strategy for PL-14, the Company’s proprietary intranasal allergy blocker for ...

New Hampshire lawmakers got into a heated debate Thursday as the House passed a bill to ban puberty blockers for children ...

Certain widely used drug combinations may either slow down or worsen the progression of Alzheimer's disease, but their ...

Studies to assess efficacy, safety, user experience, and nasal residence time as Company prepares for regulatory path forwardRaanana, Israel, ...

The debate showed a massive divide between the supporters and opponents of the bill.

A deeper understanding of a gene that predisposes patients to fatty liver disease may open new avenues for treatment of the ...

Milestone Pharmaceuticals hit another bump in the road in its quest to get Cardamyst approved for paroxysmal supraventricular ...

Certain widely used drug combinations may either slow down or worsen the progression of Alzheimer's disease, but their ...